Career Strategy
Building a U.S. Career as a Polish biotech CEO — April 2024
Everything you need to know about the latest changes and how they affect your O-1 strategy.
The legal and strategic challenge for Polish biotech founders
Foreign biotech executives who have built careers in Poland face a distinctive immigration challenge when targeting the U.S. market: the American immigration system has no dedicated visa for independent startup founders, and the most common executive visa — the L-1A intracompany transferee — requires a preexisting qualifying relationship between a foreign entity and a U.S. affiliate. Founders without an established U.S. subsidiary structure must create that structure before filing, adding time and cost to the process. The O-1A extraordinary ability visa under 8 C.F.R. § 214.2(o)(3)(ii) provides an alternative that focuses on the individual's achievement record rather than corporate architecture, making it the most practical near-term pathway for biotech founders with strong research or commercial credentials.
Poland's biotech sector has grown substantially within the European Research Framework, particularly under Horizon Europe and predecessor programs, producing researchers and entrepreneurs with publication records, patent portfolios, and competitive grant histories that are objectively significant by international standards. The challenge for U.S. immigration purposes is presentation, not substance: USCIS adjudicators are less familiar with National Science Centre (NCN) grants, NCBiR innovation awards, and Polish Academy of Sciences fellowships than with NSF CAREER awards or NIH R01 funding. A petition that contextualizes European credentials for an American audience — explaining selection rates, funding amounts relative to U.S. equivalents, and the standing of awarding institutions — can convert a strong European record into a persuasive O-1A evidentiary foundation.
The O-1A category also offers structural flexibility useful for early-stage founders. Under 8 C.F.R. § 214.2(o)(2)(iv)(E), an O-1A petition can be filed by an agent acting on behalf of the beneficiary, allowing a founder without a single U.S. employer to petition on the basis of multiple engagements — research partnerships, consulting arrangements, advisory roles, or conference invitations. This agent structure is specifically designed for individuals whose work is project-based or itinerant rather than tied to a single employer, and it allows a biotech founder to obtain initial O-1A status while the formal U.S. entity is still being organized and capitalized.
Defining the field and selecting the most defensible criteria
The field definition is the first strategic decision in an O-1A petition for a biotech CEO. A petitioner trained as a molecular biologist who later became a commercial executive has credentials in research science, drug development, and business leadership simultaneously, and the field framing determines which regulatory criteria are easiest to satisfy. Framing the field as life sciences or molecular biology directs the analysis toward scientific credentials — publications, citations, peer review, and research grants. Framing it as biotechnology entrepreneurship shifts emphasis toward business metrics, advisory roles, and industry recognition. Most O-1A petitions for biotech founders frame the field at the scientific level, where objective evidence is most abundant, and supplement with business credentials as corroborating context.
The eight O-1A criteria under 8 C.F.R. § 214.2(o)(3)(iii) include awards, membership in associations requiring outstanding achievement, published material about the petitioner, judging the work of others, original scientific contributions of major significance, scholarly articles, critical role in distinguished organizations, and high salary or remuneration relative to others. Biotech founders with research backgrounds typically have the strongest evidence in scholarly articles, original contributions, judging, and critical role. The awards criterion can be met by national research grants awarded through competitive peer review — NCN grants, NCBiR projects, and EU-funded consortium leadership all qualify if the selection process involved recognized national or international experts evaluating research merit on a competitive basis.
Practitioners preparing O-1A petitions for biotech founders should conduct a thorough credential audit before choosing which criteria to lead with. A founder with 20 peer-reviewed publications and 800 citations presents a clear scholarly articles case; a founder with two patents and a licensing agreement with a major pharmaceutical company presents a clear original contributions case. Attempting to force evidence into criteria it does not naturally satisfy produces thin, unconvincing evidence packages that invite RFEs. Lead with the strongest criteria and treat the others as supplementary corroboration. The goal is a redundant evidentiary record where USCIS skepticism on any single item does not undermine the overall petition.
Scientific publications, patents, and citation-based evidence
Peer-reviewed publications indexed in PubMed, Web of Science, or Scopus constitute the most familiar and legible form of O-1A evidence for USCIS adjudicators with STEM petition experience. Citation counts from Web of Science or Google Scholar provide a quantifiable measure of the work's influence that adjudicators can evaluate without specialized domain knowledge. A petitioner with publications in journals ranked in the upper quartile of their subfield by Journal Impact Factor, and with citations reflecting active use of the research by subsequent investigators, presents a scholarly record that is difficult to challenge. Practitioners should submit a complete publication list organized by citation count, identify the five to ten most-cited papers, and provide documentation of citation data from a verifiable, archival source.
Patent portfolios provide a distinct evidentiary pathway for founders whose primary contribution has been technological or commercial rather than academic. Utility patents issued by the USPTO or the European Patent Office for biotechnological inventions — particularly patents that have been licensed to third parties, cover a product in active clinical development, or are extensively cited by subsequent patent filers — constitute direct evidence of original contributions of major significance. The petition letter should explain each patent in accessible language: what problem the invention solves, why existing approaches were inadequate, what the petitioner's specific inventive contribution was, and what the downstream commercial or scientific impact has been. Raw patent counts without narrative context add little to the evidentiary record.
For biotech founders whose primary record is commercial — executives who have led IND filings, assembled clinical development teams, managed multinational trial sites, or structured licensing agreements with major pharmaceutical companies — the evidentiary strategy centers on the critical role criterion rather than scholarly articles. Critical role evidence for a commercial biotech executive includes board resolutions documenting the petitioner's decision-making authority, investor letters explaining that funding was contingent on the petitioner's continuing leadership, FDA correspondence identifying the petitioner as the responsible official, and expert letters from pharmaceutical industry veterans who can attest to the significance of the petitioner's operational contributions within the competitive landscape of drug development.
Remuneration, equity, and the high-salary criterion
The high salary or remuneration criterion under 8 C.F.R. § 214.2(o)(3)(iii)(H) requires evidence that the petitioner commands high remuneration relative to others in the same field. For early-stage biotech founders, cash salary is often deliberately below market as the company prioritizes capital deployment over founder compensation. This does not preclude the criterion — total compensation, including vested equity, advisory fees, board retainers from portfolio companies, and consulting income, constitutes remuneration for purposes of the analysis. The comparison group should be carefully identified: the petitioner's compensation should be benchmarked against biotech CEOs at companies of comparable stage, size, and therapeutic focus, not against the full distribution of life sciences workers, which includes laboratory technicians and research assistants.
Bureau of Labor Statistics OEWS data for chief executives (SOC 11-1011) provides a publicly verifiable baseline for remuneration comparisons, though the BLS data captures a broad cross-industry sample that includes CEOs of very large companies alongside startup founders. More precise benchmarking data for venture-backed biotech CEOs is available through Radford (now Aon) and similar compensation surveys commonly cited in the life sciences industry. Practitioners should obtain the most recent survey data available at the time of filing, cite the data source explicitly in the petition letter, and demonstrate that the petitioner's total compensation — including all forms of remuneration — exceeds the median or upper quartile for the identified peer group.
Documenting equity compensation requires care. USCIS has taken the position in some adjudications that unvested equity does not constitute current remuneration because it is contingent on future employment. Vested equity and exercised options are documentable through capitalization table excerpts, option exercise records, and accountant letters. For a founder holding a significant equity stake in a company that has received institutional venture investment, the fair market value of vested equity may substantially exceed any cash salary and represents the most significant form of total compensation. The petition letter should present the equity valuation conservatively — using the most recent financing round as the basis for fair market value — and address directly why the equity position demonstrates high remuneration relative to others in the field.
Expert letters and building a U.S. institutional presence
Expert letters are indispensable in O-1A petitions and are the vehicle through which USCIS understands the petitioner's standing within the field. The USCIS Policy Manual instructs adjudicators to give significant weight to expert opinion when it is specific, credible, and based on personal knowledge of the petitioner's work. For a biotech founder, the most effective expert letter writers are U.S.-based scientists or industry leaders who have encountered the petitioner's work directly: researchers who have cited the petitioner's publications, venture investors who evaluated the company in a competitive investment process, regulatory experts who have reviewed the petitioner's IND filing, or academic collaborators at U.S. research universities who can speak from firsthand experience about the quality of the joint work.
Building a U.S.-based expert witness network before filing requires deliberate relationship development over 12 to 18 months. Conference presentations at BIO International Convention, ASH, AACR, ASCO, or disease-specific meetings create the professional context in which U.S.-based scientists and executives encounter the petitioner's work. Collaborative grants with U.S. academic medical centers, sponsored research agreements with national laboratories, and advisory board participation at U.S. institutions generate the documented affiliations that produce credible letter writers. A Polish biotech founder who has spent a year building U.S. institutional relationships will have access to a substantially more effective expert letter pool than one who files based solely on European credentials without U.S. institutional contacts.
European experts can and should contribute letters when they have genuine expertise and firsthand knowledge of the petitioner's work. Letters from senior researchers at the Max Planck Society, EMBL, or leading European universities carry institutional credibility that USCIS can recognize. European expert letters should include a brief description of the writer's U.S. exposure and familiarity with U.S. standards — explaining that the writer has presented at U.S. conferences, collaborated with U.S. researchers, or has personal knowledge of how the petitioner's credentials compare to U.S. practitioners at a similar career stage — so that the comparative assessment has a concrete referent accessible to USCIS adjudicators evaluating the petition record.
Timing the immigration strategy with business milestones
Filing an O-1A petition before any U.S. institutional presence exists forces reliance on the petitioner's pre-U.S. record alone. A strong European research and commercial record can support an O-1A approval, but USCIS adjudicators find U.S.-contextualized evidence most legible. Filing after securing a lead U.S. institutional investor, establishing a sponsored research agreement with a U.S. university, or receiving a Phase I NIH SBIR or STTR award creates a materially stronger critical role and original contributions case and provides U.S.-credible expert witnesses who know the petitioner's work directly. The optimal filing window is typically after the company has established its first meaningful U.S. partnerships but before the petitioner's physical presence becomes operationally critical to the business.
Premium processing under 8 C.F.R. § 106.4 allows O-1A petitioners to receive a decision within 15 business days for an additional fee. For a biotech executive managing investor presentations, FDA filing timelines, and board meetings, standard processing times of two to five months are operationally unacceptable. Premium processing should be treated as the default for any O-1A petition where the petitioner has a near-term business need for U.S. presence, and practitioners should budget premium processing fees as a standard component of O-1A filing costs rather than an optional upgrade. USCIS has historically allowed premium processing upgrades after initial filing, providing a backstop if business urgency materializes after submission.
The long-term immigration strategy for a biotech founder who intends to build a permanent U.S. presence requires concurrent planning for permanent residence pathways. The O-1A visa has no hard cumulative limit on extensions but does not protect against immigrant intent complications if the petitioner also has a pending immigrant visa petition. The EB-1A immigrant visa for aliens of extraordinary ability applies the same evidentiary standard as O-1A and can be filed concurrently with O-1A status maintenance under appropriate dual-intent guidance. For founders whose work addresses an unmet medical need, the National Interest Waiver under INA § 203(b)(2)(B) provides an alternative path that can be argued on the basis of the company's pipeline, FDA filings, and national research significance.